首页 > 最新文献

Archives of internal medicine最新文献

英文 中文
HIV racial disparities: time to close the gaps. 艾滋病种族差异:是时候缩小差距了。
Pub Date : 2012-11-12 DOI: 10.1001/2013.jamainternmed.613
William Cunningham
{"title":"HIV racial disparities: time to close the gaps.","authors":"William Cunningham","doi":"10.1001/2013.jamainternmed.613","DOIUrl":"https://doi.org/10.1001/2013.jamainternmed.613","url":null,"abstract":"","PeriodicalId":8290,"journal":{"name":"Archives of internal medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/2013.jamainternmed.613","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30961240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
The influence of sex, race/ethnicity, and educational attainment on human immunodeficiency virus death rates among adults, 1993-2007. 性别、种族/民族和受教育程度对1993-2007年成人人体免疫缺陷病毒死亡率的影响。
Pub Date : 2012-11-12 DOI: 10.1001/archinternmed.2012.4508
Edgar P Simard, Mesfin Fransua, Deepa Naishadham, Ahmedin Jemal

Background: Overall declines in human immunodeficiency virus (HIV) mortality may mask patterns for subgroups, and prior studies of disparities in mortality have used area-level vs individual-level socioeconomic status measures. The aim of this study was to examine temporal trends in HIV mortality by sex, race/ethnicity, and individual level of education (as a proxy for socioeconomic status).

Methods: We examined HIV deaths among non-Hispanic white, non-Hispanic black, and Hispanic men and women aged 25 to 64 years in 26 states (1993-2007; N=91 307) reported to the National Vital Statistics System. The main outcome measures were age-standardized HIV death rates, rate differences, and rate ratios by educational attainment and between the least- and the most-educated (≤12 vs ≥16 years) individuals.

Results: Between 1993-1995 and 2005-2007, mortality declined for most men and women by race/ethnicity and educational levels, with the greatest absolute decreases for nonwhites owing to their higher baseline rates. Among men with the most education, rates per 100 000 population decreased from 117.89 (95% CI, 101.08-134.70) to 15.35 (12.08-18.62) in blacks vs from 26.42 (24.93-27.92) to 1.79 (1.50-2.08) in whites. Rates were unchanged for the least-educated black women (26.76; 95% CI, 24.30-29.23; during 2005-2007) and remained high for similarly educated black men (52.71; 48.96-56.45). Relative declines were greater with increasing levels of education (P < .001), resulting in widening disparities. Among men, the disparity rate ratio (comparing the least and the most educated) increased from 1.04 (95% CI, 0.89-1.21) during 1993-1995 to 3.43 (2.74-4.30) during 2005-2007 for blacks and from 0.98 (0.91-1.05) to 2.82 (2.34-3.40) for whites.

Conclusion: Although absolute declines in HIV mortality were greatest for nonwhites, rates remain high among blacks, especially in the lowest educated groups, underscoring the need for additional interventions.

背景:人类免疫缺陷病毒(HIV)死亡率的总体下降可能掩盖了亚组的模式,先前对死亡率差异的研究使用了地区水平与个人水平的社会经济地位测量。本研究的目的是检验按性别、种族/民族和个人教育水平(作为社会经济地位的代表)划分的艾滋病毒死亡率的时间趋势。方法:我们检查了26个州(1993-2007;N=91 307)向国家生命统计系统报告。主要结局指标是年龄标准化的艾滋病毒死亡率、发病率差异、受教育程度和受教育程度最低与最高(≤12岁vs≥16岁)个体之间的发病率比。结果:1993-1995年和2005-2007年期间,按种族/民族和教育水平划分,大多数男性和女性的死亡率下降,非白人的绝对下降幅度最大,因为他们的基线率较高。在受教育程度最高的男性中,黑人每10万人的发病率从117.89 (95% CI, 101.08-134.70)下降到15.35(12.08-18.62),而白人从26.42(24.93-27.92)下降到1.79(1.50-2.08)。受教育程度最低的黑人女性(26.76;95% ci, 24.30-29.23;在2005-2007年期间),同样受过教育的黑人男性仍然很高(52.71;48.96 - -56.45)。随着教育水平的提高,相对下降幅度更大(P < 0.001),导致差距扩大。在男性中,黑人的差距率比(比较受教育程度最低和最高的)从1993-1995年的1.04 (95% CI, 0.89-1.21)增加到2005-2007年的3.43(2.74-4.30),白人从0.98(0.91-1.05)增加到2.82(2.34-3.40)。结论:尽管艾滋病毒死亡率的绝对下降在非白人中最大,但黑人,特别是受教育程度最低的群体中的死亡率仍然很高,强调需要额外的干预措施。
{"title":"The influence of sex, race/ethnicity, and educational attainment on human immunodeficiency virus death rates among adults, 1993-2007.","authors":"Edgar P Simard,&nbsp;Mesfin Fransua,&nbsp;Deepa Naishadham,&nbsp;Ahmedin Jemal","doi":"10.1001/archinternmed.2012.4508","DOIUrl":"https://doi.org/10.1001/archinternmed.2012.4508","url":null,"abstract":"<p><strong>Background: </strong>Overall declines in human immunodeficiency virus (HIV) mortality may mask patterns for subgroups, and prior studies of disparities in mortality have used area-level vs individual-level socioeconomic status measures. The aim of this study was to examine temporal trends in HIV mortality by sex, race/ethnicity, and individual level of education (as a proxy for socioeconomic status).</p><p><strong>Methods: </strong>We examined HIV deaths among non-Hispanic white, non-Hispanic black, and Hispanic men and women aged 25 to 64 years in 26 states (1993-2007; N=91 307) reported to the National Vital Statistics System. The main outcome measures were age-standardized HIV death rates, rate differences, and rate ratios by educational attainment and between the least- and the most-educated (≤12 vs ≥16 years) individuals.</p><p><strong>Results: </strong>Between 1993-1995 and 2005-2007, mortality declined for most men and women by race/ethnicity and educational levels, with the greatest absolute decreases for nonwhites owing to their higher baseline rates. Among men with the most education, rates per 100 000 population decreased from 117.89 (95% CI, 101.08-134.70) to 15.35 (12.08-18.62) in blacks vs from 26.42 (24.93-27.92) to 1.79 (1.50-2.08) in whites. Rates were unchanged for the least-educated black women (26.76; 95% CI, 24.30-29.23; during 2005-2007) and remained high for similarly educated black men (52.71; 48.96-56.45). Relative declines were greater with increasing levels of education (P < .001), resulting in widening disparities. Among men, the disparity rate ratio (comparing the least and the most educated) increased from 1.04 (95% CI, 0.89-1.21) during 1993-1995 to 3.43 (2.74-4.30) during 2005-2007 for blacks and from 0.98 (0.91-1.05) to 2.82 (2.34-3.40) for whites.</p><p><strong>Conclusion: </strong>Although absolute declines in HIV mortality were greatest for nonwhites, rates remain high among blacks, especially in the lowest educated groups, underscoring the need for additional interventions.</p>","PeriodicalId":8290,"journal":{"name":"Archives of internal medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archinternmed.2012.4508","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30961594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 49
Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. 唑尼沙胺用于肥胖成人减肥:一项为期一年的随机对照试验。
Pub Date : 2012-11-12 DOI: 10.1001/2013.jamainternmed.99
Kishore M Gadde, Mariko F Kopping, H Ryan Wagner, Gretchen M Yonish, David B Allison, George A Bray
BACKGROUNDObese individuals who have failed to achieve adequate weight loss with lifestyle changes have limited nonsurgical therapeutic options. We evaluated the efficacy and tolerability of zonisamide, an antiepileptic drug, for enhancing weight loss in obese patients receiving diet and lifestyle guidance.METHODSThis was a 1-year, randomized, double-blind, placebo-controlled trial conducted from January 9, 2006, through September 20, 2011, at Duke University Medical Center. A total of 225 obese (mean [SD] body mass index, 37.6 [4.9]) participants included 134 women (59.6%) and 91 men (40.4%) without diabetes mellitus. (Body mass index is calculated as weight in kilograms divided by height in meters squared.) Interventions were daily dosing with placebo (n = 74), 200 mg of zonisamide (n = 76), or 400 mg of zonisamide (n = 75), in addition to diet and lifestyle counseling by a dietitian for 1 year. Primary outcome was change in body weight at 1 year.RESULTSOf the 225 randomized patients, 218 (96.9%) provided 1-year follow-up assessments. Change in body weight was -4.0 kg (95% CI, -5.8 to -2.3 kg; least squares mean, -3.7%) for placebo, -4.4 kg (-6.1 to -2.6 kg; -3.9%; P = .79 vs placebo) for 200 mg of zonisamide, and -7.3 kg (-9.0 to -5.6 kg; -6.8%; P = .009 vs placebo) for 400 mg of zonisamide. In the categorical analysis, 23 (31.1%) assigned to placebo, 26 (34.2%; P = .72) assigned to 200 mg of zonisamide, and 41 (54.7%; P = .007) assigned to 400 mg of zonisamide achieved 5% or greater weight loss; for 10% or greater weight loss, the corresponding numbers were 6 (8.1%), 17 (22.4%; P = .02), and 24 (32.0%; P < .001). Gastrointestinal, nervous system, and psychiatric adverse events occurred at a higher incidence with zonisamide than with placebo.CONCLUSIONZonisamide at the daily dose of 400 mg moderately enhanced weight loss achieved with diet and lifestyle counseling but had a high incidence of adverse events.TRIAL REGISTRATIONclinicaltrials.gov Identifier: NCT00275834
背景:通过改变生活方式未能达到适当体重减轻的肥胖者,其非手术治疗选择有限。我们评估了唑尼沙胺(一种抗癫痫药物)在接受饮食和生活方式指导的肥胖患者中促进体重减轻的疗效和耐受性。方法:这是一项为期1年的随机、双盲、安慰剂对照试验,于2006年1月9日至2011年9月20日在杜克大学医学中心进行。共有225名肥胖(平均[SD]体重指数37.6[4.9])参与者,其中134名女性(59.6%)和91名男性(40.4%)无糖尿病。(体重指数的计算方法是体重(公斤)除以身高(米)的平方。)干预措施是每天服用安慰剂(n = 74)、200毫克唑尼沙胺(n = 76)或400毫克唑尼沙胺(n = 75),此外还有1年由营养师提供的饮食和生活方式咨询。主要终点是1年时体重的变化。结果:225例随机患者中,218例(96.9%)提供了1年随访评估。体重变化为-4.0 kg (95% CI, -5.8至-2.3 kg;最小二乘平均值为-3.7%),安慰剂为-4.4 kg(-6.1至-2.6 kg;-3.9%;与安慰剂相比,P = 0.79),服用200 mg唑尼沙胺组-7.3 kg(-9.0至-5.6 kg;-6.8%;P = 0.009 vs安慰剂),400毫克唑尼沙胺。在分类分析中,23例(31.1%)被分配到安慰剂组,26例(34.2%);200 mg唑尼沙胺组(P = 0.72)和41 (54.7%;P = .007), 400 mg唑尼沙胺组体重减轻5%或更多;体重减轻10%及以上时,相应数字分别为6(8.1%)、17 (22.4%);P = .02), 24 (32.0%;P < 0.001)。唑尼沙胺组胃肠道、神经系统和精神不良事件发生率高于安慰剂组。结论:Zonisamide每日剂量为400mg,通过饮食和生活方式咨询可适度增强体重减轻,但不良事件发生率高。试验注册:clinicaltrials.gov标识符:NCT00275834
{"title":"Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial.","authors":"Kishore M Gadde,&nbsp;Mariko F Kopping,&nbsp;H Ryan Wagner,&nbsp;Gretchen M Yonish,&nbsp;David B Allison,&nbsp;George A Bray","doi":"10.1001/2013.jamainternmed.99","DOIUrl":"https://doi.org/10.1001/2013.jamainternmed.99","url":null,"abstract":"BACKGROUND\u0000Obese individuals who have failed to achieve adequate weight loss with lifestyle changes have limited nonsurgical therapeutic options. We evaluated the efficacy and tolerability of zonisamide, an antiepileptic drug, for enhancing weight loss in obese patients receiving diet and lifestyle guidance.\u0000\u0000\u0000METHODS\u0000This was a 1-year, randomized, double-blind, placebo-controlled trial conducted from January 9, 2006, through September 20, 2011, at Duke University Medical Center. A total of 225 obese (mean [SD] body mass index, 37.6 [4.9]) participants included 134 women (59.6%) and 91 men (40.4%) without diabetes mellitus. (Body mass index is calculated as weight in kilograms divided by height in meters squared.) Interventions were daily dosing with placebo (n = 74), 200 mg of zonisamide (n = 76), or 400 mg of zonisamide (n = 75), in addition to diet and lifestyle counseling by a dietitian for 1 year. Primary outcome was change in body weight at 1 year.\u0000\u0000\u0000RESULTS\u0000Of the 225 randomized patients, 218 (96.9%) provided 1-year follow-up assessments. Change in body weight was -4.0 kg (95% CI, -5.8 to -2.3 kg; least squares mean, -3.7%) for placebo, -4.4 kg (-6.1 to -2.6 kg; -3.9%; P = .79 vs placebo) for 200 mg of zonisamide, and -7.3 kg (-9.0 to -5.6 kg; -6.8%; P = .009 vs placebo) for 400 mg of zonisamide. In the categorical analysis, 23 (31.1%) assigned to placebo, 26 (34.2%; P = .72) assigned to 200 mg of zonisamide, and 41 (54.7%; P = .007) assigned to 400 mg of zonisamide achieved 5% or greater weight loss; for 10% or greater weight loss, the corresponding numbers were 6 (8.1%), 17 (22.4%; P = .02), and 24 (32.0%; P < .001). Gastrointestinal, nervous system, and psychiatric adverse events occurred at a higher incidence with zonisamide than with placebo.\u0000\u0000\u0000CONCLUSION\u0000Zonisamide at the daily dose of 400 mg moderately enhanced weight loss achieved with diet and lifestyle counseling but had a high incidence of adverse events.\u0000\u0000\u0000TRIAL REGISTRATION\u0000clinicaltrials.gov Identifier: NCT00275834","PeriodicalId":8290,"journal":{"name":"Archives of internal medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/2013.jamainternmed.99","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31045745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
About this journal. 关于这本日记。
Pub Date : 2012-11-12 DOI: 10.1001/archinte.172.20.1532
{"title":"About this journal.","authors":"","doi":"10.1001/archinte.172.20.1532","DOIUrl":"https://doi.org/10.1001/archinte.172.20.1532","url":null,"abstract":"","PeriodicalId":8290,"journal":{"name":"Archives of internal medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31496060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medical students and the Affordable Care Act: uninformed and undecided. 医学生和平价医疗法案:无知和未决定。
Pub Date : 2012-11-12 DOI: 10.1001/archinternmed.2012.3758
Tyler N A Winkelman, Ryan M Antiel, Cynthia S Davey, Jon C Tilburt, John Y Song
{"title":"Medical students and the Affordable Care Act: uninformed and undecided.","authors":"Tyler N A Winkelman,&nbsp;Ryan M Antiel,&nbsp;Cynthia S Davey,&nbsp;Jon C Tilburt,&nbsp;John Y Song","doi":"10.1001/archinternmed.2012.3758","DOIUrl":"https://doi.org/10.1001/archinternmed.2012.3758","url":null,"abstract":"","PeriodicalId":8290,"journal":{"name":"Archives of internal medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archinternmed.2012.3758","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30929003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 18
Increased mortality following telemonitoring in frail elderly patients: look before you leap! 老年体弱患者远程监护后死亡率增加:三思而后行!
Pub Date : 2012-11-12 DOI: 10.1001/archinternmed.2012.4421
Jaap Trappenburg, Rolf Groenwold, Marieke Schuurmans
T elemonitoring is often proposed as an efficient way to provide health care. The recent study by Takahashi et al examining telemonitoring in vulnerable patients with mixed chronic diseases clearly reflects the need for meticulous scientific approaches to study these types of interventions. Telemonitoring aims at early detection and prompt action in the case of health deterioration. Although patients reported high satisfaction and a sense of safety, telemonitoring failed to reduce hospital admissions and emergency department visits. Surprisingly, it resulted in a 4-fold increase in mortality risk (relative risk, 3.8; 95% CI, 1.3-11.0). This suggests that telemonitoring in frail elderly patients is hazardous, causing more harm than good. However, one can question the validity of this conclusion. A well-considered interpretation of the observed increased risk of mortality among patients receiving telemonitoring requires crucial information on timing and causes of death, which is currently lacking. The combined end point analysis ignores the true time-related impact of the exposure on mortality and health care utilization. In addition, it would have been informative to compare between-group characteristics of fatal cases vs nonfatal cases and indications for hospital admissions and emergency department visits. Despite randomization, it is not clear if both groups were comparable regarding their baseline mortality risk. An important constraint to obtain unbiased effect estimates in a randomized controlled trial (RCT) is that comparison groups are equivalent in terms of prognosis. It is well-established in statistical literature that hypothesis testing is inappropriate to evaluate differences in the distribution of baseline patient characteristics between treatment groups in RCTs. Nevertheless, the authors decided, based on P values, that both groups were balanced and adjustment of potential confounders was not necessary. It needs to be emphasized that even nonsignificant (P .05) imbalances of strong prognostic factors may still result in substantial bias and therefore requires adjustment. For example, chronic obstructive pulmonary disease, diabetes mellitus, and congestive heart failure were not statistically imbalanced between the treatment groups and yet are important risk factors of mortality and hence potentially confounding the effects of telemonitoring. These questions actually reflect the largest drawback of the study: the lack of substantial insight in the assumed relation between patient characteristics, intervention, and outcome. In intervention testing, the RCT is the final step, following a sequence of steps from initial preclinical research through phase 1 and phase 2 studies. The study by Takahashi et al warrants careful consideration of the benefits of telehealth interventions. Moreover, it shows the need of careful development and testing of nonpharmaceutical interventions.
{"title":"Increased mortality following telemonitoring in frail elderly patients: look before you leap!","authors":"Jaap Trappenburg,&nbsp;Rolf Groenwold,&nbsp;Marieke Schuurmans","doi":"10.1001/archinternmed.2012.4421","DOIUrl":"https://doi.org/10.1001/archinternmed.2012.4421","url":null,"abstract":"T elemonitoring is often proposed as an efficient way to provide health care. The recent study by Takahashi et al examining telemonitoring in vulnerable patients with mixed chronic diseases clearly reflects the need for meticulous scientific approaches to study these types of interventions. Telemonitoring aims at early detection and prompt action in the case of health deterioration. Although patients reported high satisfaction and a sense of safety, telemonitoring failed to reduce hospital admissions and emergency department visits. Surprisingly, it resulted in a 4-fold increase in mortality risk (relative risk, 3.8; 95% CI, 1.3-11.0). This suggests that telemonitoring in frail elderly patients is hazardous, causing more harm than good. However, one can question the validity of this conclusion. A well-considered interpretation of the observed increased risk of mortality among patients receiving telemonitoring requires crucial information on timing and causes of death, which is currently lacking. The combined end point analysis ignores the true time-related impact of the exposure on mortality and health care utilization. In addition, it would have been informative to compare between-group characteristics of fatal cases vs nonfatal cases and indications for hospital admissions and emergency department visits. Despite randomization, it is not clear if both groups were comparable regarding their baseline mortality risk. An important constraint to obtain unbiased effect estimates in a randomized controlled trial (RCT) is that comparison groups are equivalent in terms of prognosis. It is well-established in statistical literature that hypothesis testing is inappropriate to evaluate differences in the distribution of baseline patient characteristics between treatment groups in RCTs. Nevertheless, the authors decided, based on P values, that both groups were balanced and adjustment of potential confounders was not necessary. It needs to be emphasized that even nonsignificant (P .05) imbalances of strong prognostic factors may still result in substantial bias and therefore requires adjustment. For example, chronic obstructive pulmonary disease, diabetes mellitus, and congestive heart failure were not statistically imbalanced between the treatment groups and yet are important risk factors of mortality and hence potentially confounding the effects of telemonitoring. These questions actually reflect the largest drawback of the study: the lack of substantial insight in the assumed relation between patient characteristics, intervention, and outcome. In intervention testing, the RCT is the final step, following a sequence of steps from initial preclinical research through phase 1 and phase 2 studies. The study by Takahashi et al warrants careful consideration of the benefits of telehealth interventions. Moreover, it shows the need of careful development and testing of nonpharmaceutical interventions.","PeriodicalId":8290,"journal":{"name":"Archives of internal medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archinternmed.2012.4421","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31045748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Impact of the Screening Abdominal Aortic Aneurysms Very Efficiently (SAAAVE) Act on abdominal ultrasonography use among Medicare beneficiaries. 非常有效地筛选腹主动脉瘤(SAAAVE)法案对腹部超声检查在医疗保险受益人中的使用的影响。
Pub Date : 2012-10-22 DOI: 10.1001/archinternmed.2012.4268
Jacqueline Baras Shreibati, Laurence C Baker, Mark A Hlatky, Matthew W Mell

Background: Since January 1, 2007, Medicare has covered abdominal aortic aneurysm (AAA) screening for new male enrollees with a history of smoking under the Screening Abdominal Aortic Aneurysms Very Efficiently (SAAAVE) Act. We examined the association between this program and abdominal ultrasonography for AAA screening, elective AAA repair, hospitalization for AAA rupture, and all-cause mortality.

Methods: We used a 20% sample of traditional Medicare enrollees from 2004 to 2008 to identify 65-year-old men eligible for screening and 3 control groups not eligible for screening (70-year-old men, 76-year-old men, and 65-year-old women). We used logistic regression to examine the change in outcomes at 365 days for eligible vs ineligible beneficiaries before and after SAAAVE Act implementation, adjusting for comorbidities, state-level smoking prevalence, geographic variation, and time trends.

Results: Fewer than 3% of abdominal ultrasonography claims after 2007 were for SAAAVE-specific AAA screening. There was a significantly greater increase in abdominal ultrasonography use among SAAAVE-eligible beneficiaries (2.0 percentage points among 65-year-old men, from 7.6% in 2004 to 9.6% in 2008; 0.7 points [8.9% to 9.6%] among 70-year-old men; 0.7 points [10.8% to 11.5%] among 76-year-old men; and 0.9 points [7.5% to 8.4%] among 65-year-old women) (P < .001 for all comparisons with 65-year-old men). The SAAAVE Act was associated with increased use of abdominal ultrasonography in 65-year-old men compared with 70-year-old men (adjusted odds ratio [AOR], 1.15; 95% CI, 1.11-1.19) (P < .001), and this increased use remained even when SAAAVE-specific AAA screening was excluded (AOR, 1.12; 95% CI, 1.08-1.16) (P < .001). Implementation of the SAAAVE Act was not associated with changes in rates of AAA repair, AAA rupture, or all-cause mortality.

Conclusions: The impact of the SAAAVE Act on AAA screening was modest and was based on abdominal ultrasonography use that it did not directly reimburse. The SAAAVE Act had no discernable effect on AAA rupture or all-cause morality.

背景:自2007年1月1日起,根据《高效腹主动脉瘤筛查法案》(SAAAVE),医疗保险对有吸烟史的男性新入选者进行了腹主动脉瘤(AAA)筛查。我们研究了该方案与腹部超声检查AAA筛查、选择性AAA修复、AAA破裂住院和全因死亡率之间的关系。方法:我们使用2004年至2008年20%的传统医疗保险参保者样本来确定符合筛查条件的65岁男性和3个不符合筛查条件的对照组(70岁男性、76岁男性和65岁女性)。我们使用逻辑回归来检查在SAAAVE法案实施前后,符合条件的受益人与不符合条件的受益人在365天内的结果变化,调整了合并症、州水平的吸烟率、地理差异和时间趋势。结果:2007年以后,腹部超声检查中只有不到3%是针对saaave特异性的AAA筛查。在符合saaave条件的受益人中,腹部超声检查的使用明显增加(65岁男性中2.0个百分点,从2004年的7.6%增加到2008年的9.6%;70岁男性为0.7分(8.9% - 9.6%);76岁男性为0.7分(10.8%至11.5%);65岁女性为0.9分[7.5%至8.4%])(与65岁男性的所有比较P < 0.001)。与70岁男性相比,SAAAVE法案与65岁男性腹部超声检查的使用增加有关(调整优势比[AOR], 1.15;95% CI, 1.11-1.19) (P < 0.001),即使排除saaave特异性AAA筛查,这种增加的使用仍然存在(AOR, 1.12;95% ci, 1.08-1.16) (p < 0.001)。SAAAVE法案的实施与AAA级修复率、AAA级破裂率或全因死亡率的变化无关。结论:SAAAVE法案对AAA筛查的影响是适度的,并且是基于腹部超声检查的使用,它没有直接报销。SAAAVE法案对AAA破裂或全因道德没有明显的影响。
{"title":"Impact of the Screening Abdominal Aortic Aneurysms Very Efficiently (SAAAVE) Act on abdominal ultrasonography use among Medicare beneficiaries.","authors":"Jacqueline Baras Shreibati,&nbsp;Laurence C Baker,&nbsp;Mark A Hlatky,&nbsp;Matthew W Mell","doi":"10.1001/archinternmed.2012.4268","DOIUrl":"https://doi.org/10.1001/archinternmed.2012.4268","url":null,"abstract":"<p><strong>Background: </strong>Since January 1, 2007, Medicare has covered abdominal aortic aneurysm (AAA) screening for new male enrollees with a history of smoking under the Screening Abdominal Aortic Aneurysms Very Efficiently (SAAAVE) Act. We examined the association between this program and abdominal ultrasonography for AAA screening, elective AAA repair, hospitalization for AAA rupture, and all-cause mortality.</p><p><strong>Methods: </strong>We used a 20% sample of traditional Medicare enrollees from 2004 to 2008 to identify 65-year-old men eligible for screening and 3 control groups not eligible for screening (70-year-old men, 76-year-old men, and 65-year-old women). We used logistic regression to examine the change in outcomes at 365 days for eligible vs ineligible beneficiaries before and after SAAAVE Act implementation, adjusting for comorbidities, state-level smoking prevalence, geographic variation, and time trends.</p><p><strong>Results: </strong>Fewer than 3% of abdominal ultrasonography claims after 2007 were for SAAAVE-specific AAA screening. There was a significantly greater increase in abdominal ultrasonography use among SAAAVE-eligible beneficiaries (2.0 percentage points among 65-year-old men, from 7.6% in 2004 to 9.6% in 2008; 0.7 points [8.9% to 9.6%] among 70-year-old men; 0.7 points [10.8% to 11.5%] among 76-year-old men; and 0.9 points [7.5% to 8.4%] among 65-year-old women) (P < .001 for all comparisons with 65-year-old men). The SAAAVE Act was associated with increased use of abdominal ultrasonography in 65-year-old men compared with 70-year-old men (adjusted odds ratio [AOR], 1.15; 95% CI, 1.11-1.19) (P < .001), and this increased use remained even when SAAAVE-specific AAA screening was excluded (AOR, 1.12; 95% CI, 1.08-1.16) (P < .001). Implementation of the SAAAVE Act was not associated with changes in rates of AAA repair, AAA rupture, or all-cause mortality.</p><p><strong>Conclusions: </strong>The impact of the SAAAVE Act on AAA screening was modest and was based on abdominal ultrasonography use that it did not directly reimburse. The SAAAVE Act had no discernable effect on AAA rupture or all-cause morality.</p>","PeriodicalId":8290,"journal":{"name":"Archives of internal medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archinternmed.2012.4268","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30912463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 70
Needling the status quo. 针刺现状。
Pub Date : 2012-10-22 DOI: 10.1001/archinternmed.2012.4198
Andrew L Avins
{"title":"Needling the status quo.","authors":"Andrew L Avins","doi":"10.1001/archinternmed.2012.4198","DOIUrl":"https://doi.org/10.1001/archinternmed.2012.4198","url":null,"abstract":"","PeriodicalId":8290,"journal":{"name":"Archives of internal medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archinternmed.2012.4198","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30894676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Resuming anticoagulation in the first week following gastrointestinal tract hemorrhage: should we adopt a 4-day rule? 胃肠道出血后第一周恢复抗凝:是否应采用4天规则?
Pub Date : 2012-10-22 DOI: 10.1001/archinternmed.2012.4309
Daniel J Brotman, Amir K Jaffer
{"title":"Resuming anticoagulation in the first week following gastrointestinal tract hemorrhage: should we adopt a 4-day rule?","authors":"Daniel J Brotman,&nbsp;Amir K Jaffer","doi":"10.1001/archinternmed.2012.4309","DOIUrl":"https://doi.org/10.1001/archinternmed.2012.4309","url":null,"abstract":"","PeriodicalId":8290,"journal":{"name":"Archives of internal medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archinternmed.2012.4309","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30912648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Acupuncture for chronic pain: individual patient data meta-analysis. 针灸治疗慢性疼痛:患者个体数据荟萃分析。
Pub Date : 2012-10-22 DOI: 10.1001/archinternmed.2012.3654
Andrew J Vickers, Angel M Cronin, Alexandra C Maschino, George Lewith, Hugh MacPherson, Nadine E Foster, Karen J Sherman, Claudia M Witt, Klaus Linde

Background: Although acupuncture is widely used for chronic pain, there remains considerable controversy as to its value. We aimed to determine the effect size of acupuncture for 4 chronic pain conditions: back and neck pain, osteoarthritis, chronic headache, and shoulder pain.

Methods: We conducted a systematic review to identify randomized controlled trials (RCTs) of acupuncture for chronic pain in which allocation concealment was determined unambiguously to be adequate. Individual patient data meta-analyses were conducted using data from 29 of 31 eligible RCTs, with a total of 17 922 patients analyzed.

Results: In the primary analysis, including all eligible RCTs, acupuncture was superior to both sham and no-acupuncture control for each pain condition (P < .001 for all comparisons). After exclusion of an outlying set of RCTs that strongly favored acupuncture, the effect sizes were similar across pain conditions. Patients receiving acupuncture had less pain, with scores that were 0.23 (95% CI, 0.13-0.33), 0.16 (95% CI, 0.07-0.25), and 0.15 (95% CI, 0.07-0.24) SDs lower than sham controls for back and neck pain, osteoarthritis, and chronic headache, respectively; the effect sizes in comparison to no-acupuncture controls were 0.55 (95% CI, 0.51-0.58), 0.57 (95% CI, 0.50-0.64), and 0.42 (95% CI, 0.37-0.46) SDs. These results were robust to a variety of sensitivity analyses, including those related to publication bias.

Conclusions: Acupuncture is effective for the treatment of chronic pain and is therefore a reasonable referral option. Significant differences between true and sham acupuncture indicate that acupuncture is more than a placebo. However, these differences are relatively modest, suggesting that factors in addition to the specific effects of needling are important contributors to the therapeutic effects of acupuncture.

背景:尽管针灸被广泛用于治疗慢性疼痛,但对其价值仍存在相当大的争议。我们旨在确定针灸治疗 4 种慢性疼痛病症的效果大小:背痛和颈痛、骨关节炎、慢性头痛和肩痛:我们对针灸治疗慢性疼痛的随机对照试验(RCT)进行了系统回顾,这些试验的分配隐藏被明确认定为充分。我们利用 31 项符合条件的 RCT 中 29 项的数据进行了患者个体数据荟萃分析,共分析了 17 922 名患者:结果:在包括所有符合条件的 RCT 的主要分析中,针灸在每种疼痛条件下均优于假针灸和无针灸对照(所有比较中 P < .001)。在排除了一组强烈倾向于针灸的异常研究后,各种疼痛情况下的效应大小相似。接受针灸治疗的患者疼痛减轻,其评分分别比假对照组低 0.23(95% CI,0.13-0.33)、0.16(95% CI,0.07-0.25)和 0.15(95% CI,0.07-0.在背部和颈部疼痛、骨关节炎和慢性头痛方面,与假对照组相比,效应大小分别为 0.55(95% CI,0.51-0.58)、0.57(95% CI,0.50-0.64)和 0.42(95% CI,0.37-0.46)SDs;与无针灸对照组相比,效应大小分别为 0.55(95% CI,0.51-0.58)、0.57(95% CI,0.50-0.64)和 0.42(95% CI,0.37-0.46)SDs。这些结果在各种敏感性分析(包括与发表偏倚相关的分析)中都很稳健:针灸对治疗慢性疼痛有效,因此是一种合理的转诊选择。真针灸与假针灸之间的显著差异表明,针灸比安慰剂更有效。然而,这些差异相对较小,表明除了针刺的特殊效果外,其他因素也是针灸治疗效果的重要因素。
{"title":"Acupuncture for chronic pain: individual patient data meta-analysis.","authors":"Andrew J Vickers, Angel M Cronin, Alexandra C Maschino, George Lewith, Hugh MacPherson, Nadine E Foster, Karen J Sherman, Claudia M Witt, Klaus Linde","doi":"10.1001/archinternmed.2012.3654","DOIUrl":"10.1001/archinternmed.2012.3654","url":null,"abstract":"<p><strong>Background: </strong>Although acupuncture is widely used for chronic pain, there remains considerable controversy as to its value. We aimed to determine the effect size of acupuncture for 4 chronic pain conditions: back and neck pain, osteoarthritis, chronic headache, and shoulder pain.</p><p><strong>Methods: </strong>We conducted a systematic review to identify randomized controlled trials (RCTs) of acupuncture for chronic pain in which allocation concealment was determined unambiguously to be adequate. Individual patient data meta-analyses were conducted using data from 29 of 31 eligible RCTs, with a total of 17 922 patients analyzed.</p><p><strong>Results: </strong>In the primary analysis, including all eligible RCTs, acupuncture was superior to both sham and no-acupuncture control for each pain condition (P < .001 for all comparisons). After exclusion of an outlying set of RCTs that strongly favored acupuncture, the effect sizes were similar across pain conditions. Patients receiving acupuncture had less pain, with scores that were 0.23 (95% CI, 0.13-0.33), 0.16 (95% CI, 0.07-0.25), and 0.15 (95% CI, 0.07-0.24) SDs lower than sham controls for back and neck pain, osteoarthritis, and chronic headache, respectively; the effect sizes in comparison to no-acupuncture controls were 0.55 (95% CI, 0.51-0.58), 0.57 (95% CI, 0.50-0.64), and 0.42 (95% CI, 0.37-0.46) SDs. These results were robust to a variety of sensitivity analyses, including those related to publication bias.</p><p><strong>Conclusions: </strong>Acupuncture is effective for the treatment of chronic pain and is therefore a reasonable referral option. Significant differences between true and sham acupuncture indicate that acupuncture is more than a placebo. However, these differences are relatively modest, suggesting that factors in addition to the specific effects of needling are important contributors to the therapeutic effects of acupuncture.</p>","PeriodicalId":8290,"journal":{"name":"Archives of internal medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658605/pdf/nihms467452.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30894187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Archives of internal medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1